St. Joseph, Missouri —Triangle® vaccines, long-time staples of the Fort Dodge Animal Health vaccine line, now have a new look and updated names. As part of the expanded Boehringer Ingelheim Vetmedica, Inc. portfolio, Triangle® 5 has replaced Triangle® 4 + Type II BVD, and Triangle® 10 replaces Triangle® 9 + Type II BVD.
Triangle 5 and Triangle 10 will also appear in a bottle with a new green label this summer. The familiar Fort Dodge Animal Health yellow label has been replaced by a green label. This green label will be more closely aligned with the design of the Boehringer Ingelheim Vetmedica family of products.
Although the packaging for Triangle 5 and Triangle 10 has changed, beef and dairy cattle producers will still find the same powerful protection from this killed virus vaccine to aid in the prevention of disease caused by bovine respiratory syncytial virus (BRSV), bovine viral diarrhea (BVD) Types 1 and 2, parainfluenza 3 (PI3) and infectious bovine rhinotracheitis (IBR). Triangle 10 also aids in the prevention of disease caused by five serovars of Leptospira (L.canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona).
For more information on Triangle 5 or Triangle 10, contact your veterinarian or Boehringer Ingelheim Vetmedica, Inc. representative.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit: www.bi-vetmedica.com.